Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-08

Prime Medicine (PRME)

CEO Allan Reine was paid $3,894,187 in fiscal year 2025, ↓ down 15.8% from fiscal year 2024 (SEC filing 0001628280-26-026697 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,894,187 ↓
Allan Reine total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

PRME's next annual pay disclosure, estimated April 24, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Allan Reine$606,212$0$0$2,828,798$402,000$0$57,177$3,894,187
Chief Executive Officer
Keith Gottesdiener259,568001,185,80200762,4002,207,770
Former Chief Executive Officer
Ann Lee505,37500790,075243,960010,7061,550,116
Chief Technical Officer
Jeremy Duffield268,27100668,60000380,9261,317,797
Former Chief Scientific Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Allan Reine$3,894,187$4,623,802—↓ −729,615
Keith Gottesdiener2,207,7702,245,6175,403,071↓ −37,847
Ann Lee1,550,116———
Jeremy Duffield1,317,797———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Prime Medicine's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper PRME reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against PRME
8 companies name PRME as a compensation peer

The list of companies that name PRME as a peer is temporarily unavailable — recheck shortly.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Allan ReineCEO$3,894,187
Jeremy DuffieldChief Scientific Officer$1,317,797
Ann LeeChief Technical Officer$1,550,116
Keith GottesdienerChief Executive Officer$2,207,770
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
David Schenkein, M.DIndependent Director$196,424
Jeffrey D. MarrazzoDirector$1,340,110
Kaye FosterIndependent Director$222,359
Michael KellyIndependent Director$227,079
Robert NelsenIndependent Director$186,424
Thomas Cahill, M.D., Ph.DIndependent Director$193,924
Wendy Chung, M.D., Ph.DIndependent Director$222,079
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Michael KellyDirector2026-06-05A75,000$0$0Derivative, Class A CommonForm 4 ↗
Robert NelsenDirector2026-06-05A75,00000Derivative, Class A CommonForm 4 ↗
Thomas CahillDirector2026-06-05A75,00000Derivative, Class A CommonForm 4 ↗
Jeffrey D. MarrazzoDirector2026-06-05A75,00000Derivative, Class A CommonForm 4 ↗
David P. SchenkeinDirector2026-06-05A75,00000Derivative, Class A CommonForm 4 ↗
Wendy ChungDirector2026-06-05A75,00000Derivative, Class A CommonForm 4 ↗
Kaye I. Foster-CheekDirector2026-06-05A75,00000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Jeremy DuffieldOPTION2025-02-27————$275,000
Allan Reine, M.D.OPTION2025-02-27—275,000275,000—471,598
Allan Reine, M.D.OPTION2025-08-01—850,000850,000—445,801
Allan Reine, M.D.OPTION2025-05-19—2,000,0002,000,000—1,911,400
Keith GottesdienerOPTION2025-02-28————500,000
Ann LeeOPTION2025-08-01——180,995—197,786
Ann LeeOPTION2025-08-01——180,995—120,691
Ann LeeOPTION2025-02-27——275,000—471,598
Jeremy Duffield FRCPOPTION2025-02-27——275,000—471,598
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Jeremy Duffield$0$0$275,0000.0%
Allan Reine, M.D.002,828,7990.0%
Keith Gottesdiener00500,0000.0%
Ann Lee00790,0750.0%
Jeremy Duffield FRCP00471,5980.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Jeremy DuffieldOption98,0398.49—
Keith GottesdienerOption54,1678.32—
Jeremy DuffieldOption217,7092.42—
Allan ReineOption217,7092.42—
Jeremy DuffieldOption56,56112.3—
Allan ReineOption2,000,0001.34—
Allan ReineOption312,5004.04—
Keith GottesdienerOption155,54412.3—
Keith GottesdienerOption395,8342.52—
Ann LeeOption217,7092.42—
Ann LeeOption98,0394.04—
Ann LeeOption56,5614.04—
05

Incentive-plan design — the Compensation Discussion & Analysis

The executive compensation program is designed to attract, motivate and retain key employees who we believe best represent our values and can make significant contributions towards achieving our purpose of delivering a new class of differentiated one-time curative genetic therapies to address the widest spectrum of diseases by deploying our Prime Editing technology.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)—
Independent consultantAlpine Rewards
Clawback policytrue
Anti-hedging—
Anti-pledging—
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-08-01—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-08-01—a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Jeffrey D. MarrazzoNot independent$45,000—$1,199,949—$95,161$1,340,110
Michael KellyIndependent · Audit Committee (Chair)65,000—162,079—0227,079
Kaye FosterIndependent · Compensation Committee (Chair)60,000—162,359—0222,359
Wendy Chung, M.D., Ph.DIndependent · Audit · Nominating and Corporate Governance60,0000162,07900222,079
David Schenkein, M.DIndependent · Compensation · Nominating and Corporate Governance (Chair)62,500—133,924—0196,424
Thomas Cahill, M.D., Ph.DIndependent · Audit · Nominating and Corporate Governance60,0000133,92400193,924
Robert NelsenIndependent · Compensation Committee52,500—133,924—0186,424
Allan Reine, M.DEmployee director—————0
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)10,000 / 15,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$405,000
Equity awards (grant-date value)$0
All other compensation$95,161
Total cost of the board$500,161

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Prime Medicine2025Allan Reine$606,212$0$2,828,798$402,000$3,894,187

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Prime Medicine in fiscal 2025?
As disclosed, Allan Reine (Chief Executive Officer) was the highest-paid executive at Prime Medicine in fiscal 2025, with total compensation of $3,894,187.
How much does Prime Medicine spend in total on board compensation for fiscal 2025?
As disclosed, Prime Medicine reported total board compensation of $500,161 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Allan ReineDEF 14A2026-04-230001628280-26-026697Section “Executive Compensation”. As printed: 3,894,187. Filing ↗machine: r2 · c42 · span 285179–285188
2Section 01, Keith GottesdienerDEF 14A2026-04-230001628280-26-026697Section “Executive Compensation”. As printed: 2,207,770. Filing ↗machine: r4 · c42 · span 291171–291180
3Section 01, Ann LeeDEF 14A2026-04-230001628280-26-026697Section “Executive Compensation”. As printed: 1,550,116. Filing ↗machine: r6 · c42 · span 297131–297140
4Section 01, Jeremy DuffieldDEF 14A2026-04-230001628280-26-026697Section “Executive Compensation”. As printed: 1,317,797. Filing ↗machine: r8 · c42 · span 301287–301296
5Section 03, Jeremy Duffield OPTIONDEF 14A2026-04-230001628280-26-026697Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r4 · c4 · span 200486–200493
6Section 03, Allan Reine, M.D. OPTIONDEF 14A2026-04-230001628280-26-026697Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r2 · c10 · span 195599–195606
7Section 03, Allan Reine, M.D. OPTIONDEF 14A2026-04-230001628280-26-026697Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r8 · c10 · span 213485–213492
8Section 03, Allan Reine, M.D. OPTIONDEF 14A2026-04-230001628280-26-026697Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r6 · c10 · span 207534–207543
9Section 03, Keith Gottesdiener OPTIONDEF 14A2026-04-230001628280-26-026697Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r5 · c4 · span 203458–203465
10Section 03, Ann Lee OPTIONDEF 14A2026-04-230001628280-26-026697Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 216451–216458
11Section 03, Ann Lee OPTIONDEF 14A2026-04-230001628280-26-026697Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 219418–219425
12Section 03, Ann Lee OPTIONDEF 14A2026-04-230001628280-26-026697Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 198613–198620
13Section 03, Jeremy Duffield FRCP OPTIONDEF 14A2026-04-230001628280-26-026697Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 201595–201602
14Section 07, pay ratio10-K2026-03-030001628280-26-013569Section “CEO Pay Ratio”. As printed: —. Filing ↗
15Section 08, Jeffrey D. MarrazzoDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 1,340,110. Filing ↗machine: span 239148–239456
16Section 08, Michael KellyDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 227,079. Filing ↗machine: span 237175–237481
17Section 08, Kaye FosterDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 222,359. Filing ↗machine: span 235209–235515
18Section 08, Wendy Chung, M.D., Ph.DDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 222,079. Filing ↗machine: span 232080–232321
19Section 08, David Schenkein, M.DDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 196,424. Filing ↗machine: span 243090–243396
20Section 08, Thomas Cahill, M.D., Ph.DDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 193,924. Filing ↗machine: span 229895–230162
21Section 08, Robert NelsenDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 186,424. Filing ↗machine: span 241116–241422
22Section 08, Allan Reine, M.DDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 0. Filing ↗
23Section 02, Michael Kelly 2026-06-05Form 42026-06-080001628280-26-041569Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Robert Nelsen 2026-06-05Form 42026-06-080001628280-26-041572Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Thomas Cahill 2026-06-05Form 42026-06-080001628280-26-041553Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Jeffrey D. Marrazzo 2026-06-05Form 42026-06-080001628280-26-041575Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, David P. Schenkein 2026-06-05Form 42026-06-080001628280-26-041579Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Wendy Chung 2026-06-05Form 42026-06-080001628280-26-041560Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Kaye I. Foster-Cheek 2026-06-05Form 42026-06-080001628280-26-041566Insider equity transaction reported since the proxy statement. Filing ↗
30Section 06, 2025 voteForm 8-K2025-08-050001628280-25-037840Item 5.07 · say-on-pay result. As reported: — (votes for as printed: 71,563,193). Filing ↗
31Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
32Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
33Section 09b board cost (computed)Computed——Cash 405,000 + equity 0 + all other 95,161 = 500,161, summed across the director compensation table rows.machine: formula: Σ = 500,161
34Prime Medicine (subject), Section 10b CEO totalDEF 14A2026-04-230001628280-26-026697CEO total compensation as printed in Prime Medicine's own proxy. As printed: 3,894,187. Filing ↗machine: r2 · c42 · span 285179–285188

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.